Dobakhti Faramarz, Zargar Ali, Naghibi Taraneh
Department of Pharmaceutics, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran.
Research Committee, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Bull Emerg Trauma. 2023;11(1):26-31. doi: 10.30476/BEAT.2023.97509.1406.
Ventilator-associated pneumonia is the common cause of morbidity and mortality in the intensive care unit. Due to the antimicrobial effect of chlorhexidine, and the long-lasting result of mucoadhesive drugs, this study aimed to determine the effect of chlorhexidine mucoadhesive gel on the prevention of ventilator-associated pneumonia in critical patients.
In this clinical trial, 64 ventilated patients were selected and randomly allocated into two groups. The first group received 0.2% chlorhexidine mucoadhesive gel and the second group received 0.2% chlorhexidine solution as a mouthwash. Every three days, the incidence of ventilator-associated pneumonia was evaluated by the clinical score of pulmonary infection. The data were analyzed by SPSS statistical software version 20.
There was no statistically significant difference in demographic characteristics between the two groups. In the control group, 25% of the patients had ventilator-associated pneumonia, while it was only 15.6% in the intervention group; however, the incidence of ventilator-associated pneumonia revealed no significant difference between the two groups (HR ratio, 0.86; 95% confidence interval, 0.49 to 1.83 0.356).In addition, there was no statistically significant difference between the number of days connected to the ventilator ( 0.854), the number of days hospitalized in the intensive care unit ( 0.423), and the death rate ( 0.634) between the two groups.
Although no significant statistical difference was detected between chlorhexidine mucoadhesive gel and chlorhexidine solution in the prevention of ventilator-associated pneumonia, the incidence of pneumonia in the mucoadhesive gel group was clinically less than in the control group. It is better to repeat the study with a larger statistical population.
呼吸机相关性肺炎是重症监护病房发病和死亡的常见原因。由于氯己定的抗菌作用以及粘膜粘附药物的长效作用,本研究旨在确定氯己定粘膜粘附凝胶对预防重症患者呼吸机相关性肺炎的效果。
在这项临床试验中,选取64例使用呼吸机的患者并随机分为两组。第一组接受0.2%氯己定粘膜粘附凝胶,第二组接受0.2%氯己定溶液作为漱口液。每三天通过肺部感染临床评分评估呼吸机相关性肺炎的发生率。数据采用SPSS 20.0统计软件进行分析。
两组患者的人口统计学特征无统计学显著差异。对照组中25%的患者发生了呼吸机相关性肺炎,而干预组仅为15.6%;然而,两组之间呼吸机相关性肺炎的发生率无显著差异(风险比,0.86;95%置信区间,0.49至1.83,P = 0.356)。此外,两组在呼吸机使用天数(P = 0.854)、重症监护病房住院天数(P = 0.423)和死亡率(P = 0.634)方面均无统计学显著差异。
虽然在预防呼吸机相关性肺炎方面,氯己定粘膜粘附凝胶与氯己定溶液之间未检测到显著的统计学差异,但粘膜粘附凝胶组的肺炎发生率在临床上低于对照组。最好用更大的统计样本重复该研究。